Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!

Zhen Su, CEO at Marengo Therapeutics, posted the following on LinkedIn:

“Phase III NSCLC Ivonescimab (Anti-VEGF/PD-1 Bispecific) from Akeso Inc. vs. Pembrolizumab (Anti PD-1) topline results are out at WCLC. PFS HR: 0.51 H2H and benefits observed across all major subgroups. Congratulations to AKESOBIO team! Really excited to see the next-gen IO reagents (bispecific IO) continue to push the boundaries higher for better patient care.

Still more to learn why it worked so well. But for the NSCLC patients who were enrolled in the investigational arm… doubling progress free survival is what matters!”

Source: Zhen Su/LinkedIn